SP
ALNY icon

SIH Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

SIH Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,073
Closed -$355K – 327
2026
Q1 		$355K Buy
+1,073
New +$365K ﹤0.01% 233
2025
Q4 		– Sell
-1,020
Closed -$465K – 210
2025
Q3 		$465K Buy
+1,020
New +$415K 0.01% 164
2025
Q2 		– Sell
-7,959
Closed -$2.15M – 173
2025
Q1 		$2.15M Buy
+7,959
New +$2.05M 0.07% 85

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIH Partners's ALNY Position: Q2 2026 in Review

SIH Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 1,073 shares — an estimated $355K sold.

SIH Partners first reported a position in ALNY in Q1 2025 and held it in 3 quarters. The position peaked at $2.15M in Q1 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • SIH Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • SIH Partners sold 1,073 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $355K.
  • SIH Partners first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • SIH Partners's Alnylam Pharmaceuticals position peaked at $2.15M in Q1 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on SIH Partners's 13F filing for Q2 2026, filed 14 Aug 2026.